HistoCyte Laboratories Ltd – Trademark Portfolio
Entity Type: 99
HistoCyte Laboratories Ltd holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 2 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include HISTOCYTE LABORATORIES.
The Neon Building, Quorum Park,
Benton Lane Newcastle Upon Tyne NE12 8BU
Showing of trademarks Trademarks
Trademark Classifications
HistoCyte Laboratories Ltd's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does HistoCyte Laboratories Ltd have?
HistoCyte Laboratories Ltd has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does HistoCyte Laboratories Ltd file in?
HistoCyte Laboratories Ltd files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are HistoCyte Laboratories Ltd's most well-known trademarks?
HistoCyte Laboratories Ltd's registered trademark portfolio includes well-known marks such as HISTOCYTE LABORATORIES. These are among 2 currently registered trademarks in the portfolio.
What is HistoCyte Laboratories Ltd's trademark registration success rate?
HistoCyte Laboratories Ltd has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.